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Objectives: Beneﬁt from asymptomatic carotid endar-
terectomy (AsCEA) depends on long-term survival. We
undertook this study to examine 5-year survival (5-ys) in
octogenarians after AsCEA.
Methods: National Medicare data from 2006-2011
was used to examine 5-ys in patients aged $80 who un-
derwent elective AsCEA in 2006 without evidence of
TIA or stroke 180 days before surgery. We calculated
overall mortality and used Kaplan-Meier curves to
examine 5-ys. We built Cox proportional hazards
(CPH) models to examine the independent predictors
of survival after AsCEA.
Results: In 2006 16,616 patients aged $80 years un-
derwent AsCEA; 1.3% died #30 days of surgery. Overall,
the probability of 5-ys was 0.56 (95% conﬁdence interval
[CI], 0.55-0.57). A multivariate CPH model identiﬁed
the following comorbidities (COM) as having a signiﬁcant
effect on 5-ys (hazard ratio, 95% CI): COPD (1.45, 1.37-
1.53), CHF (1.90, 1.78-2.03), diabetes (1.10, 1.04-
1.16), renal failure (1.74, 1.62-1.86), and valve disease
(1.23, 1.15-1.32). Age and COM both affected 5-ys,
with the probability of survival ranging from 0.71 (95%
CI, 0.69-0.74) for an 80-year-old (yo) with no COM to
0.18 (95% CI, 0.04-0.38) for a $85-yo with three
COM (P < .01. Conversely, a $85-yo with no COM
had survival superior to an 80-yo with three COM
(0.53 [95% CI, 0.51-0.55] vs 0.34 [95% CI, 0.23-
0.45]; P < .01) (Table).
Conclusions: Although AsCEA may be appropriate
for some older Americans, this study demonstrates that
many octogenarians do not live long enough to derive
beneﬁt. Careful selection is essential.Table. Probability of 5-ys after AsCEA by age and
number of comorbidities
Age, years
No. of Comorbidities
0 1 2 3
Overall 0.64 0.53 0.40 0.29
80 0.71 0.63 0.47 0.34
81 0.71 0.59 0.49 0.42
82 0.69 0.53 0.40 0.31
83 0.67 0.54 0.39 0.33
84 0.65 0.52 0.45 0.25
$85 0.63 0.43 0.32 0.18
All SEs <0.07.
Table. 30-day Results: Early vs Delayed CEA
30-day Results
Overall Early CEA Delayed CEA
P
(n ¼ 322) (n ¼ 100) (n ¼222)
No. (%) No. (%) No. (%)
Death 0 0 0 .
MAE 8 (2.5) 3 (3) 5 (2.2) .7
Any stroke 4 (1.2) 3 (3) 1(0.4) .1
Minor stroke 2 (0.6) 2 (2) 0 .1
Major stroke 2 (0.6) 1 (1)
(Hemorrhagic)
1(0.4)
(Ischemic)
.5
Disabling stroke 2 (0.6) 1 (1) 1 (0.4) .5
Myocardial infarct 4 (1.2) 0 4 (1.8) .3
30-day neurologic status
Improved (decrease
NHISS $1)
43 (13.3) 19 (19) 24 (10.8) .03
Unchanged 275 (85.4) 78 (78) 197 (88.7) .01
Impaired 4 (1.2) 3 (3) 1 (0.4) .1
CEA, Carotid endarterectomy; MAE, major adverse event (composite of
stroke, death, and myocardial infarct); NHISS, National Institutes of Health
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Objectives: To determine 30-day neurologic improve-
ment (NI) with respect to the timing of carotid endarterec-
tomy (CEA) in symptomatic stable patients.
Methods: Patients included underwent consecutive
CEAs (2009-2013) for symptomatic carotid stenosis
$60%. They had a National Institutes of Health Stroke
Scale (NIHSS) score <5 on presentation. Patients were
divided according to time between the qualifying event
and surgery (0-14 days, n ¼ 100: early CEA; 15-30
days, n ¼ 222: delayed CEA). Outcomes were death,
stroke, myocardial infarct (MI), 30-day major adverse
event (MAE) rate (composite of stroke, death, and
MI), and NI deﬁned as a NIHSS score decrease ($1)
rate at 30 days. Independent neurologic assessment was
performed.
Results: Type of qualifying symptoms (stroke vs tran-
sient ischemic attack) was similar. Early CEA patients had a
higher American Society of Anesthesiologists physical sta-
tus risk (P ¼ .0001) and were more under dual antiplatelet
therapy (P ¼ .02). Outcomes are summarized in the Table.
Thirty-day NI was associated with early CEA (odds ratio,
1.9; 95% conﬁdence interval, 1.0-3.7; P ¼ .03).
Conclusions: Our results suggest that reducing the
time for intervention in selected (NIHSS <5) and stable
symptomatic patients is safe and associated with neurologic
status improvement at 30 days.
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High-Risk Carotid Endarterectomy (CEA) Beyond the
SAPPHIRE Trial and Development of a Risk Index to
Deﬁne Patients At Risk for Adverse Outcomes After
CEA, From the Vascular Study Group of New
England (VSGNE)
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Objectives: Recently we deﬁned several independent
high-risk criteria that were inclusive and exclusive of the
SAPPHIRE (Stenting with Angioplasty and Protection in
Patients at High Risk for Endarterectomy) trial. The objec-
tive of this study was to create a risk index that may predict
patients at high risk for carotid endarterectomy (CEA).
Methods: Data on 3,098 CEAs between 2003 and
2011 at 20 Vascular Study Group of New England
(VSGNE) centers were used for this study. SAPPHIRE
general inclusion criteria and primary outcomes of death,
stroke, or myocardial infarction were used, as were other
previously reported high-risk criteria. Factors that were
associated with the primary outcome by analysis of variance
(P < .10) and not linearly dependent, as determined by a
Pearson’s correlation analysis, were further assessed for an
independent association by multivariate logistic regression.
A risk index model was developed for these signiﬁcant pre-
dictors using an integer score as a reliable formula.
Results: Multivariate analysis (P < .05) found the
following independently signiﬁcant risk factors (95% conﬁ-
dence interval): age in years (1.0-1.1; P < .001), preadmis-
sion nursing home (1.2-6.6; P ¼ .020), congestive heart
failure (CHF; 1.4-2.8; P < .001), diabetes (1.1-1.3; P <
.001), chronic obstructive pulmonary disease (COPD;
1.2-1.5; P < .001), any previous cerebrovascular disease
(CVD; 1.1-1.9; P ¼ .003), and contralateral internal ca-
rotid artery stenosis (1.0-1.2; P ¼ .001). The predictors
are age in years (40-49: 0 points; 50-59: 2 points; 60-69:
4 points; 70-79: 6 points; 80-89: 8 points), living in a
nursing home (4 points), any CVD (2 points), CHF (5
points), COPD (3 points), diabetes (2 points), degree of
contralateral stenosis (<50%: 0 points; 50-69%: 1 point;
70-near occlusion: 2 points; occlusion: 3 points). Lowest-
risk CEA was deﬁned as 0 points with an estimated risk
of 2.7%, highest-risk CEA was deﬁned as >13 points, rep-
resenting adverse outcome rate of 22.5%.
Conclusions: The SAPPHIRE high-risk CEA deﬁni-
tion is not accurate. We propose a new, evidence-baseddeﬁnition of high-risk CEA. The CEA risk index model
may assist clinicians in appropriate patient selection. Future
studies should aim at validation of this risk index model.
Author Disclosures: R. Botta: Nothing to disclose; M.
Fokkema: Nothing to disclose; L. Gates: Nothing to
disclose; P. P. Goodney: Nothing to disclose; J. Indes:
Nothing to disclose; B. W. Nolan: Nothing to disclose;
M. L. Schermerhorn: Nothing to disclose; F. Schlosser:
Nothing to disclose.
RR7.
Long-Term Analysis of California Hospital Discharges
Suggests Gender Differences in Survival and Ischemic
Stroke Rates in Asymptomatic Patients Undergoing
Carotid Endarterectomy (CEA) or Stenting (CAS)
David L. Ku, Natalia N. Egorova, Eugene A. Sosunov,
Joseph Song, Alan Moskowitz, Michael Marin, Peter L.
Faries, Ageliki Vouyouka. Icahn School of Medicine at
Mount Sinai, New York, NY
Objectives: There is an ongoing debate regarding the
role of carotid interventions in asymptomatic patients, espe-
cially women. We sought to compare immediate and long-
termoutcomes in asymptomaticmenandwomenundergoing
carotid artery stenting (CAS) or carotid endarterectomy
(CEA).
Methods: We identiﬁed 27,531 hospitalizations of
asymptomatic patients with CEA or CAS among 2005-
2009 California discharges by International Classiﬁcation
of Diseases, Ninth Revision-Clinical Modiﬁcation codes.
Baseline characteristics were compared, and propensity
scores were calculated with a logistic regression model
that adjusted for clinical differences. Thirty-day mortality
and adverse neurologic event rates as well as 4-year survival
and ischemic stroke rates were analyzed in populations
matched by gender and procedure.
Results: There were 10,399 women and 13,765 men
with CEA and 1,421 women and 1,946 men with CAS. In
unmatched populations, CAS compared with CEA was
associated with more 30-day neurologic events for both
women (3.3% vs 2.4%; P ¼ .012) and men (4.1%
vs 2.9%; P ¼ .011). This difference persisted in matched
populations. There was no difference in 30-day mortality
with or without matching. When compared with CEA
during 4 years of follow-up, unmatched patients after
CAS had inferior overall survival irrespective of whether
they were female (79.3% vs 82.8%; P ¼ .006) or male
(74.7% vs 80.5%; P < .001). Men compared with women
experienced worse survival after CAS (P ¼ .006) or CEA
(P < .001). However, after CEA, women at 4 years had
higher ischemic stroke rates than men (4.6% vs 3.3%; P
< .001) but similar rates of ischemic strokes after CAS.
These gender differences persisted in matched popula-
tions. After matching, CEA vs CAS patients experienced
fewer ischemic strokes among men (3.6% vs 4.4%; P ¼
.044), but not among women.
Conclusions: CAS compared with CEA patients had
worse long-term survival in both genders and more
ischemic strokes in men. Women had better survival
regardless of procedure, whereas men with CEA had less
ischemic strokes over 4 years. These results should be taken
into account during counseling for carotid intervention.
